Characterisation of infections in patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent

被引：29

作者：

On, Sandy ^{[1
]}

Rath, Carolyn G. ^{[2
]}

Lan, Michelle ^{[3
]}

Wu, Bobby ^{[4
]}

Lau, Kimberly M. ^{[1
]}

Cheung, Edna ^{[1
]}

Alegria, William ^{[5
]}

Young, Rebecca ^{[2
]}

Tan, Marisela ^{[2
]}

Kim, Carrie ^{[4
]}

Phun, Jennifer ^{[4
]}

Patel, Nimish ^{[11
]}

Mannis, Gabriel ^{[6
]}

Logan, Aaron C. ^{[7
]}

Kennedy, Vanessa ^{[7
]}

Goodman, Aaron ^{[8
]}

Taplitz, Randy A. ^{[9
]}

Young, Patricia A. ^{[10
]}

Wen, Raymond ^{[11
]}

Saunders, Ila M. ^{[11
]}

机构：

[1] Stanford Hlth Care, Dept Pharm, Stanford, CA USA

[2] Univ Calif San Francis Hlth, Dept Pharmaceut Serv, San Francisco, CA USA

[3] Univ Calif San Diego Hlth, Dept Pharm, San Francisco, CA USA

[4] Univ Calif Los Angeles Hlth, Dept Pharm, Los Angeles, CA USA

[5] Stanford Hlth Care, Dept Qual Patient Safety & Effectiveness, Stanford, CA USA

[6] Stanford Univ, Stanford Canc Inst, Div Hematol, Stanford, CA 94305 USA

[7] Univ Calif San Francisco Hlth, Div Hematol & Oncol, San Francisco, CA 94143 USA

[8] Univ Calif San Diego Hlth, Dept Med, Div Blood & Marrow Transplant, La Jolla, CA USA

[9] City Hope Med Ctr, Dept Med, Duarte, CA USA

[10] Univ Calif Los Angeles, Div Hematol Oncol, Med Ctr, Los Angeles, CA USA

[11] Univ Calif San Diego, Skaggs Sch Pharm & Pharmaceut Sci, La Jolla, CA 92093 USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷 / 01期

关键词：

acute myeloid leukaemia; fungal infections; hypomethylating agent; infectious complications; venetoclax; INVASIVE FUNGAL-INFECTIONS; AZACITIDINE; MANAGEMENT; AML;

D O I：

10.1111/bjh.18051

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We investigated the incidence of invasive fungal infections (IFIs) and other infectious complications in patients receiving venetoclax and hypomethylating agent therapy for acute myeloid leukaemia (AML). This retrospective, multicentre cohort study included adult patients with AML who received at least one cycle of venetoclax and either azacitidine or decitabine between January 2016 and August 2020. The primary outcome was the incidence of probable or confirmed IFI. Secondary outcomes included antifungal prophylaxis prescribing patterns, incidence of bacterial infections, and incidence of neutropenic fever hospital admissions. Among 235 patients, the incidence of probable or confirmed IFI was 5.1%. IFI incidence did not differ significantly according to age, antifungal prophylaxis use, or disease status. In the subgroup of patients with probable or confirmed IFIs, six (50%) were receiving antifungal prophylaxis at the time of infection. The overall incidence of developing at least one bacterial infection was 33.6% and 127 (54%) patients had at least one hospital admission for febrile neutropenia. This study demonstrated an overall low risk of developing probable or confirmed IFI as well as a notable percentage of documented bacterial infections and hospital admissions due to neutropenic fever.

引用

页码：63 / 70

页数：8

共 24 条

[1] Optimizing venetoclax dose in combination with low intensive therapies in elderly patients with newly diagnosed acute myeloid leukemia: An exposure-response analysis [J].

Agarwal, Suresh ;

Gopalakrishnan, Sathej ;

Mensing, Sven ;

Potluri, Jalaja ;

Hayslip, John ;

Kirschbrown, Whitney ;

Friedel, Anna ;

Menon, Rajeev ;

Salem, Ahmed Flamed .

HEMATOLOGICAL ONCOLOGY, 2019, 37 (04) :464-473

[2] Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments [J].

Agarwal, Suresh K. ;

DiNardo, Courtney D. ;

Potluri, Jalaja ;

Dunbar, Martin ;

Kantarjian, Hagop M. ;

Humerickhouse, Rod A. ;

Wong, Shekman L. ;

Menon, Rajeev M. ;

Konopleva, Marina Y. ;

Salem, Ahmed Hamed .

CLINICAL THERAPEUTICS, 2017, 39 (02) :359-367

[3] Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents [J].

Aldoss, Ibrahim ;

Dadwal, Sanjeet ;

Zhang, Jianying ;

Tegtmeier, Bernard ;

Mei, Matthew ;

Arslan, Shukaib ;

Al Malki, Monzr M. ;

Salhotra, Amandeep ;

Ali, Haris ;

Aribi, Ahmed ;

Sandhu, Karamjeet ;

Khaled, Samer ;

Snyder, David ;

Nakamura, Ryotaro ;

Stein, Anthony S. ;

Forman, Stephen J. ;

Marcucci, Guido ;

Pullarkat, Vinod .

BLOOD ADVANCES, 2019, 3 (23) :4043-4049

[4]

[Anonymous], Acute Myeloid Leukemia v1.2022

[5] Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia [J].

Cornely, Oliver A. ;

Maertens, Johan ;

Winston, Drew J. ;

Perfect, John ;

Ullmann, Andrew J. ;

Walsh, Thomas J. ;

Helfgott, David ;

Holowiecki, Jerzy ;

Stockelberg, Dick ;

Goh, Yeow-Tee ;

Petrini, Mario ;

Hardalo, Cathy ;

Suresh, Ramachandran ;

Angulo-Gonzalez, David .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (04) :348-359

[6] Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia [J].

DiNardo, C. D. ;

Jonas, B. A. ;

Pullarkat, V. ;

Thirman, M. J. ;

Garcia, J. S. ;

Wei, A. H. ;

Konopleva, M. ;

Doehner, H. ;

Letai, A. ;

Fenaux, P. ;

Koller, E. ;

Havelange, V. ;

Leber, B. ;

Esteve, J. ;

Wang, J. ;

Pejsa, V. ;

Hajek, R. ;

Porkka, K. ;

Illes, A. ;

Lavie, D. ;

Lemoli, R. M. ;

Yamamoto, K. ;

Yoon, S. -S. ;

Jang, J. -H. ;

Yeh, S. -P. ;

Turgut, M. ;

Hong, W. -J. ;

Zhou, Y. ;

Potluri, J. ;

Pratz, K. W. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (07) :617-629

[7] Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia [J].

DiNardo, Courtney D. ;

Pratz, Keith ;

Pullarkat, Vinod ;

Jonas, Brian A. ;

Arellano, Martha ;

Becker, Pamela S. ;

Frankfurt, Olga ;

Konopleva, Marina ;

Wei, Andrew H. ;

Kantarjian, Hagop M. ;

Xu, Tu ;

Hong, Wan-Jen ;

Chyla, Brenda ;

Potluri, Jalaja ;

Pollyea, Daniel A. ;

Letai, Anthony .

BLOOD, 2019, 133 (01) :7-17

[8] Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies [J].

DiNardo, Courtney D. ;

Rausch, Caitlin R. ;

Benton, Christopher ;

Kadia, Tapan ;

Jain, Nitin ;

Pemmaraju, Naveen ;

Daver, Naval ;

Covert, Wendy ;

Marx, Kayleigh R. ;

Mace, Morgan ;

Jabbour, Elias ;

Cortes, Jorge ;

Garcia-Manero, Guillermo ;

Ravandi, Farhad ;

Bhalla, Kapil N. ;

Kantarjian, Hagop ;

Konopleva, Marina .

AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (03) :401-407

[9] Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study [J].

DiNardo, Courtney L. ;

Pratz, Keith W. ;

Letai, Anthony ;

Jonas, Brian A. ;

Wei, Andrew H. ;

Thirman, Michael ;

Arellano, Martha ;

Frattini, Mark G. ;

Kantarjian, Hagop ;

Popovic, Relja ;

Chyla, Brenda ;

Xu, Tu ;

Dunbar, Martin ;

Agarwal, Suresh K. ;

Humerickhouse, Rod ;

Mabry, Mack ;

Potluri, Jalaja ;

Konopleva, Marina ;

Pollyea, Daniel A. .

LANCET ONCOLOGY, 2018, 19 (02) :216-228

[10] Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel [J].

Doehner, Hartmut ;

Estey, Elihu ;

Grimwade, David ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Larson, Richard A. ;

Levine, Ross L. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel ;

Sierra, Jorge ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wei, Andrew H. ;

Lowenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2017, 129 (04) :424-447

← 1 2 3 →